AbbVie Historical Balance Sheet
ABBV Stock | USD 210.01 1.95 0.92% |
Trend analysis of AbbVie Inc balance sheet accounts such as Total Assets of 85.7 B, Other Current Liabilities of 30.4 B or Total Current Liabilities of 20.2 B provides information on AbbVie's total assets, liabilities, and equity, which is the actual value of AbbVie Inc to its prevalent stockholders. By breaking down trends over time using AbbVie balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining AbbVie Inc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether AbbVie Inc is a good buy for the upcoming year.
AbbVie Inventory |
|
AbbVie |
About AbbVie Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of AbbVie Inc at a specified time, usually calculated after every quarter, six months, or one year. AbbVie Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of AbbVie and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which AbbVie currently owns. An asset can also be divided into two categories, current and non-current.
AbbVie Balance Sheet Chart
Add Fundamental
Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Property Plant And Equipment Net
The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.Good Will
An intangible asset that arises when a company acquires another business for more than the fair market value of its net identifiable assets, representing the value of the brand, customer base, and other intangible factors.Most accounts from AbbVie's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into AbbVie Inc current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. At this time, AbbVie's Other Current Liabilities is fairly stable compared to the past year. Other Liabilities is likely to climb to about 38.3 B in 2025, whereas Total Assets are likely to drop slightly above 85.7 B in 2025.
2022 | 2023 | 2024 | 2025 (projected) | Other Current Liabilities | 22.5B | 27.0B | 29B | 30.5B | Total Assets | 138.8B | 134.7B | 135.2B | 85.7B |
AbbVie balance sheet Correlations
Click cells to compare fundamentals
AbbVie Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AbbVie balance sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Common Stock Shares Outstanding | 1.7B | 1.8B | 1.8B | 1.8B | 2.0B | 1.8B | |
Total Assets | 150.6B | 146.5B | 138.8B | 134.7B | 135.2B | 85.7B | |
Other Current Liab | 17.9B | 19.8B | 22.5B | 27.0B | 29B | 30.5B | |
Total Current Liabilities | 28.7B | 35.2B | 29.5B | 37.8B | 38.7B | 20.2B | |
Total Stockholder Equity | 13.1B | 15.4B | 17.3B | 10.4B | 3.3B | 3.2B | |
Other Liab | 18.5B | 30.4B | 31.0B | 31.7B | 36.5B | 38.3B | |
Property Plant And Equipment Net | 5.2B | 5.1B | 4.9B | 5.0B | 5.1B | 3.7B | |
Net Debt | 77.6B | 66.9B | 54.1B | 46.6B | 61.6B | 34.6B | |
Accounts Payable | 2.3B | 2.9B | 2.9B | 3.7B | 2.9B | 1.9B | |
Cash | 8.4B | 9.7B | 9.2B | 12.8B | 5.5B | 10.2B | |
Non Current Assets Total | 126.4B | 118.6B | 110.3B | 101.7B | 109.6B | 61.9B | |
Other Assets | 1.9B | 5.1B | 4.1B | 4.8B | 5.6B | 5.8B | |
Cash And Short Term Investments | 8.5B | 9.8B | 9.2B | 12.8B | 5.6B | 10.7B | |
Net Receivables | 8.8B | 10.0B | 11.3B | 11.2B | 10.9B | 7.2B | |
Good Will | 33.1B | 32.4B | 32.2B | 32.3B | 35.0B | 19.9B | |
Short Term Investments | 30M | 84M | 28M | 2M | 31M | 29.5M | |
Liabilities And Stockholders Equity | 150.6B | 146.5B | 138.8B | 134.7B | 135.2B | 85.7B | |
Non Current Liabilities Total | 108.8B | 95.9B | 92.0B | 86.5B | 93.0B | 58.6B | |
Inventory | 3.3B | 3.1B | 3.6B | 4.1B | 4.2B | 2.3B | |
Other Stockholder Equity | 15.1B | 15.2B | 14.7B | 13.6B | 13.1B | 7.6B | |
Total Liab | 137.5B | 131.1B | 121.5B | 124.3B | 131.8B | 78.8B | |
Property Plant And Equipment Gross | 5.2B | 10.7B | 11.0B | 11.6B | 12.3B | 12.9B | |
Total Current Assets | 24.2B | 27.9B | 28.5B | 33.0B | 25.6B | 23.8B | |
Accumulated Other Comprehensive Income | (3.1B) | (2.9B) | (2.2B) | (2.3B) | (1.9B) | (2.0B) | |
Intangible Assets | 82.9B | 76.0B | 67.4B | 55.6B | 60.1B | 34.5B | |
Property Plant Equipment | 3.0B | 5.2B | 5.1B | 4.9B | 5.7B | 3.4B | |
Long Term Debt | 77.6B | 64.2B | 59.1B | 52.2B | 60.3B | 43.0B | |
Short Long Term Debt Total | 86.1B | 76.7B | 63.3B | 59.4B | 67.1B | 51.7B | |
Non Currrent Assets Other | 4.9B | 4.9B | 5.6B | 8.5B | 9.1B | 9.6B | |
Short Term Debt | 8.5B | 12.5B | 4.1B | 7.2B | 6.8B | 5.4B | |
Net Tangible Assets | (42.4B) | (102.9B) | (96.2B) | (82.3B) | (74.1B) | (77.8B) | |
Noncontrolling Interest In Consolidated Entity | 21M | 28M | 33M | 37M | 42.6M | 44.7M | |
Retained Earnings | 1.1B | 3.1B | 4.8B | (1B) | (7.9B) | (7.5B) | |
Retained Earnings Total Equity | 4.7B | 1.1B | 3.1B | 4.8B | 5.5B | 3.4B | |
Long Term Debt Total | 63.0B | 77.6B | 64.2B | 59.1B | 68.0B | 50.1B | |
Capital Surpluse | 15.2B | 17.4B | 18.3B | 19.2B | 22.1B | 15.8B | |
Additional Paid In Capital | 17.4B | 18.3B | 19.2B | 20.2B | 23.2B | 15.0B |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for AbbVie Stock Analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.